AMYT:LSE-Amryt Pharma plc (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 143.00

Change

0.00 (0.00)%

Market Cap

GBX 0.46B

Volume

0.09M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Amryt Pharma plc (AMYT) Stock Analysis:
Based on the Amryt Pharma plc stock forecasts from 0 analysts, the average analyst target price for Amryt Pharma plc is not available over the next 12 months. Amryt Pharma plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Amryt Pharma plc is Slightly Bullish , which is based on 3 positive signals and 2 negative signals. At the last closing, Amryt Pharma plc’s stock price was GBX 143.00. Amryt Pharma plc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -12.00% over the last year.

No recent analyst target price found for Amryt Pharma plc
No recent average analyst rating found for Amryt Pharma plc

About

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therap ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

-48.00 (-2.78%)

GBX3.82B 11.56 5.55
INDV:LSE Indivior PLC

-0.20 (-0.07%)

GBX2.13B 16.17 6.34
HCM:LSE HUTCHMED (China) Limited

-10.80 (-6.14%)

GBX1.52B 17.41 N/A
APH:LSE Alliance Pharma plc

-5.40 (-4.75%)

GBX0.60B 85.85 18.40
BXP:LSE Beximco Pharmaceuticals Limite..

N/A

GBX0.36B 13.12 0.10
BMK:LSE Benchmark Holdings plc

+4.00 (+9.30%)

GBX0.31B N/A 14.61
ANCR:LSE Animalcare Group plc

N/A

GBX0.18B 3,350.00 19.10
AGY:LSE Allergy Therapeutics plc

N/A

GBX0.14B 53.13 364.98
EAH:LSE ECO Animal Health Group plc

N/A

GBX0.08B 14.94 3.22
VLG:LSE Venture Life Group plc

-2.75 (-7.75%)

GBX0.04B 116.67 12.31

ETFs Containing AMYT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.23% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.23% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -14.63% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.63% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.51% 15% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.51% 15% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 12.42% 100% A+ 85% B
Risk Adjusted Return -76.55% 8% F 3% F
Market Capitalization 0.46B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.92 N/A N/A N/A N/A
Price / Cash Flow Ratio 17.01 N/A N/A N/A N/A
EV/EBITDA 260.86 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -46.00% N/A N/A N/A N/A
Return on Invested Capital -15.69% N/A N/A N/A N/A
Return on Assets 0.71% N/A N/A N/A N/A
Debt to Equity Ratio 284.82% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.20 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.